Innovent Biologics, Inc. (HKG:1801)
102.50
+2.00 (1.99%)
Oct 8, 2025, 11:44 AM HKT
Innovent Biologics Revenue
Innovent Biologics had revenue of 5.95B CNY in the half year ending June 30, 2025, with 120.36% growth. This brings the company's revenue in the last twelve months to 11.42B, up 53.18% year-over-year. In the year 2024, Innovent Biologics had annual revenue of 9.42B with 51.82% growth.
Revenue (ttm)
11.42B CNY
Revenue Growth
+53.18%
P/S Ratio
13.75
Revenue / Employee
2.02M CNY
Employees
5,659
Market Cap
172.13B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.42B | 3.22B | 51.82% |
Dec 31, 2023 | 6.21B | 1.65B | 36.21% |
Dec 31, 2022 | 4.56B | 286.65M | 6.71% |
Dec 31, 2021 | 4.27B | 425.91M | 11.08% |
Dec 31, 2020 | 3.84B | 2.80B | 266.94% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
WuXi Biologics | 21.98B |
Sino Biopharmaceutical | 33.49B |
Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
Akeso | 2.75B |
CSPC Pharmaceutical Group | 28.49B |
Innovent Biologics News
- 15 days ago - Innovent's weight-loss drug highlights China challenge for Novo, Lilly - Reuters
- 18 days ago - Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes - PRNewsWire
- 20 days ago - Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2) - PRNewsWire
- 22 days ago - Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025 - PRNewsWire
- 27 days ago - Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions - GlobeNewsWire
- 4 weeks ago - Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were ... - GuruFocus
- 4 weeks ago - Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress - PRNewsWire
- 5 weeks ago - Innovent Biologics estimates ~50% jump in 2025 revenue - Seeking Alpha